Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2

Hepatology Research

Volumn 42, Issue 6, 2012, Pages 549-557

  Yamaguchi, Yasunori ^a   Tamori, Akihiro ^a   Tanaka, Yasuhito ^b   Iwai, Shuji ^a   Kobayashi, Sawako ^a   Fujii, Hideki ^a   Morikawa, Hiroyasu ^a   Hagihara, Atsushi ^a   Enomoto, Masaru ^a   Kawada, Norifumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Extended therapy; Rapid responder; Slow responder

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAPID VIRAL RESPONSE; RESPONSE GUIDED THERAPY; SUSTAINED VIRAL RESPONSE; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84860678628     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00956.x     Document Type: Article

References (28)

1. Lauer G, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Alter MJ. Global epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.
3. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005; 3: 241-9.
4. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
6. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
7. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype1 infection. N Engl J Med 2011; 364: 1195-206.
8. von Wagner M, Huber M, Berg T etal. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.
9. Mangia A, Santoro R, Minerva N etal. Peginterferon alfa-2b and ribavirin for 12 vs. 24weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
10. Yu ML, Dai CY, Huang JF etal. A randomised study of peginterferon and ribavirin for 16 versus 24weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
11. Shiffman ML, Suter F, Bacon BR etal. Peginterferon alfa-2a and ribavirin for 16 or 24weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
12. Dalgard O, Bjøro K, Ring-Larsen H etal. Pegylated interferon alfa and ribavirin for 14 versus 24weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42.
13. Lagging M, Langeland N, Pedersen C etal. Randomized comparison of 12 or 24weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 1837-45.
14. Watanabe S, Enomoto N, Koike K etal. Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res 2010; 40: 135-44.
15. Chayama K, Hayes CN, Yoshioka K etal. Factors predictive of sustained virological response following 72weeks of combination therapy for genotype 1b hepatitis C. J Gastroenterol 2011; 46: 545-55.
16. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 1688-94.
17. Di Martino V, Richou C, Cervoni JP etal. Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized controlled trials and implications for the future. Hepatology 2011; 54: 789-800.
18. Okamoto H, Tokita H, Sakamoto M etal. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74: 2385-90.
19. Nishida N, Tanabe T, Takasu M etal. Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. Anal Biochem 2007; 364: 78-85.
20. Iwasaki Y, Shiratori Y, Hige S etal. A randomized trial of 24 versus 48weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. Hepatol Int 2009; 3: 468-79.
21. Ghany MG, Strader DB, Thomas DL etal. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
22. Kumada H, Okanoue T, Onji M etal. The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8-13.
23. Kawaoka T, Hayes CN, Ohishi W etal. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54: 408-14.
24. Yu ML, Huang CF, Huang JF etal. Role of Interleukin-28B Polymorphisms in the Treatment of Hepatitis C Virus Genotype 2 Infection in Asian Patients. Hepatology 2011; 53: 7-13.
25. Sakamoto N, Nakagawa M, Tanaka Y etal. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol 2011; 83: 871-8.
26. Mangia A, Thompson AJ, Santoro R, Piazzolla V etal. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-7.
27. Mangia A, Thompson AJ, Santoro R etal. Limited utility of IL28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011; 54: 722-80.
28. Foster GR, Hézode C, Bronowicki JP etal. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but Not 3 infections. Gastroenterology 2011; 141: 881-9.